Αρχειοθήκη ιστολογίου

Πέμπτη 27 Ιουλίου 2017

MYSTIC interim results: any future for tremelimumab?

by ecancer reporter Will Davies According to today's reports, the combination of durvalumab and tremelimumab in the MYSTIC trial has failed, at an interim analysis, to extend progression free survival for EGFR/ALK lung cancer. This has delivered a...

from # All Medicine by Alexandros G. Sfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/2tNe47N
via IFTTT

Δεν υπάρχουν σχόλια:

Δημοσίευση σχολίου

Medicine by Alexandros G. Sfakianakis,Anapafseos 5 Agios Nikolaos 72100 Crete Greece,00302841026182,00306932607174,alsfakia@gmail.com,

Αναζήτηση αυτού του ιστολογίου

! # Ola via Alexandros G.Sfakianakis on Inoreader